These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 21083385

  • 1. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW.
    N Engl J Med; 2010 Nov 18; 363(21):1991-2003. PubMed ID: 21083385
    [Abstract] [Full Text] [Related]

  • 2. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
    Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS, VX08-770-102 Study Group.
    N Engl J Med; 2011 Nov 03; 365(18):1663-72. PubMed ID: 22047557
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM, VX16-659-101 Study Group.
    N Engl J Med; 2018 Oct 25; 379(17):1599-1611. PubMed ID: 30334693
    [Abstract] [Full Text] [Related]

  • 5. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
    Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D, VX09-809-102 study group.
    Lancet Respir Med; 2014 Jul 25; 2(7):527-38. PubMed ID: 24973281
    [Abstract] [Full Text] [Related]

  • 6. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, Ratjen F.
    Lancet Respir Med; 2013 Oct 25; 1(8):630-638. PubMed ID: 24461666
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC, VX14-809-109 investigator group.
    Lancet Respir Med; 2017 Jul 25; 5(7):557-567. PubMed ID: 28606620
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
    Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, Ordoñez CL, Ahrens R, VX08-770-103 (ENVISION) Study Group.
    Am J Respir Crit Care Med; 2013 Jun 01; 187(11):1219-25. PubMed ID: 23590265
    [Abstract] [Full Text] [Related]

  • 9. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE, VX 08-770-104 Study Group.
    Chest; 2012 Sep 01; 142(3):718-724. PubMed ID: 22383668
    [Abstract] [Full Text] [Related]

  • 10. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R, VX17-445-102 Study Group.
    N Engl J Med; 2019 Nov 07; 381(19):1809-1819. PubMed ID: 31697873
    [Abstract] [Full Text] [Related]

  • 11. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW.
    Cochrane Database Syst Rev; 2015 Mar 26; (3):CD009841. PubMed ID: 25811419
    [Abstract] [Full Text] [Related]

  • 12. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP, TRAFFIC Study Group, TRANSPORT Study Group.
    N Engl J Med; 2015 Jul 16; 373(3):220-31. PubMed ID: 25981758
    [Abstract] [Full Text] [Related]

  • 13. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT, VX11-661-101 Study Group.
    Am J Respir Crit Care Med; 2018 Jan 15; 197(2):214-224. PubMed ID: 28930490
    [Abstract] [Full Text] [Related]

  • 14. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
    Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC.
    N Engl J Med; 2017 Nov 23; 377(21):2024-2035. PubMed ID: 29099333
    [Abstract] [Full Text] [Related]

  • 15. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP, VX09-809-102 Study Group.
    Ann Am Thorac Soc; 2017 Feb 23; 14(2):213-219. PubMed ID: 27898234
    [Abstract] [Full Text] [Related]

  • 16. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
    Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Robertson S, Green Y, Cooke J, Rosenfeld M, KIWI Study Group.
    Lancet Respir Med; 2016 Feb 23; 4(2):107-15. PubMed ID: 26803277
    [Abstract] [Full Text] [Related]

  • 17. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.
    Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, Accurso FJ, Dong Q, Ordoñez CL, Stone AJ, Olson ER, Clancy JP, VX06-770-101 Study Group.
    PLoS One; 2013 Feb 23; 8(7):e66955. PubMed ID: 23922647
    [Abstract] [Full Text] [Related]

  • 18. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
    Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS.
    N Engl J Med; 2017 Nov 23; 377(21):2013-2023. PubMed ID: 29099344
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS, VX17-445-103 Trial Group.
    Lancet; 2019 Nov 23; 394(10212):1940-1948. PubMed ID: 31679946
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M, VX11-770-110 (KONDUCT) Study Group.
    Lancet Respir Med; 2015 Jul 23; 3(7):524-33. PubMed ID: 26070913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.